The use of aminoglutethimide (orimeten) in disseminated breast cancer

Administration of orimeten (aminoglutethimide), for disseminated breast cancer in 38 postmenopausal females, in whom other treatment modalities had failed, proved effective in 39%. Patients who had failed on tamoxifen responded to orimeten. Such side-effects as skin rash, drowsiness and cardiovascul...

Full description

Saved in:
Bibliographic Details
Published inVoprosy onkologij Vol. 33; no. 5; p. 79
Main Authors Nadezhdina, T M, Vyshinskaia, G V, Lichinitser, M R, Bassalyk, L S, Garin, A M
Format Journal Article
LanguageRussian
Published Russia (Federation) 1987
Subjects
Adult
Aminoglutethimide - adverse effects
Aminoglutethimide - therapeutic use
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Breast Neoplasms - physiopathology
Female
Follow-Up Studies
Humans
Menopause
Middle Aged
Neoplasm Metastasis
Receptors, Estrogen - drug effects
Online AccessGet more information

Cover

More Information
Summary:Administration of orimeten (aminoglutethimide), for disseminated breast cancer in 38 postmenopausal females, in whom other treatment modalities had failed, proved effective in 39%. Patients who had failed on tamoxifen responded to orimeten. Such side-effects as skin rash, drowsiness and cardiovascular disturbances were not pronounced. Limiting toxicity was 6%.
ISSN:0507-3758